US › Healthcare

Tango Therapeutics Inc (TNGX)

US · Healthcare · Biotechnology

$29.36+7.90%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-45.5M
Profit YoY
-14.1%
EPS
$-0.32
EPS estimate
$-0.30

EPS came in at -0.32 against a street estimate of -0.30 — a miss of 7.9%.

Key statistics

Market cap
$4.43B
Forward P/E
0.0
P/B
11.31
Book value
$2.72
EPS (TTM)
$-0.83
52-week high
$34.39
52-week low
$6.21
50-day MA
$27.39
200-day MA
$17.46
Beta
1.13

Analyst view

Analysts rate Tango Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $44.33.

Shareholding

Insiders
1.17%
Institutions
114.78%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC8.17%
Adage Capital Partners Gp LLC7.87%
Boxer Capital Management, LLC6.68%
TCG Crossover Management, LLC6.47%
FMR Inc6.08%
Farallon Capital Management, L.L.C.5.59%
BlackRock Inc5.37%
Woodline Partners LP4.91%

Recent filings & reports

DocumentDate
Board / officer change · Q2 20262026-06-23
Material agreement · Q2 20262026-06-10
Reg FD disclosure · Q2 20262026-06-08
Shareholder vote results · Q2 20262026-06-04
Quarterly report · Q1 20262026-05-13
Proxy statement · Q2 20262026-04-17
Annual report FY20252026-03-05
Quarterly report · Q3 20252025-11-04

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tango Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.